Tissue Tek O.C.T. Compound
To Order Contact us: lieven@wlsolutions.be
Compound 112254 |
||
| GL3740-10 | 10 | EUR 139.6 |
Compound 112254 |
||
| GL3740-50 | 50 | EUR 440.4 |
Compound 401 |
||
| 1657-5 | each | EUR 285.6 |
Compound 401 |
||
| B7337-10 | 10 mg | EUR 268.8 |
Compound 401 |
||
| B7337-25 | 25 mg | EUR 529.2 |
Compound 401 |
||
| B7337-5 | 5 mg | EUR 216 |
Compound 401 |
||
| HY-19341 | 10mM/1mL | EUR 223.2 |
Compound 1 |
||
| 1688-5 | each | EUR 248.4 |
Compound W |
||
| 2208-250 | each | EUR 360 |
Compound W |
||
| 2208-50 | each | EUR 138 |
Compound 34 |
||
| 1898-1000 | each | EUR 548.4 |
Compound 34 |
||
| 1898-200 | each | EUR 189.6 |
Compound E |
||
| 1949-1000 | each | EUR 444 |
Compound E |
||
| 1949-250 | each | EUR 183.6 |
Compound W |
||
| A4401-50 | 50 mg | EUR 212.4 |
|
Description: Inhibitor of ?-secretase; causes a decrease in the released levels of A?42 and notch-1 A?-like peptide 25 (N?25). |
||
Compound 56 |
||
| A8197-.5 | 500 µg | EUR 129.6 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-5 | 5 mg | EUR 268.8 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-5.1 | 10 mM (in 1mL DMSO) | EUR 324 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound 56 |
||
| A8197-S | Evaluation Sample | EUR 97.2 |
|
Description: Compound 56, 4-[(3-Bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR) showing an IC50 of 0.006 nM. |
||
Compound K |
||
| N1890-20 | 20 mg | EUR 408 |
|
Description: Compound K |
||
Compound 34 |
||
| GL2080-1MG | 1 mg | EUR 447.6 |
Compound 34 |
||
| GL2080-200UG | 200 ug | EUR 199.2 |
Compound E |
||
| GL3746-1MG | 1 mg | EUR 453.6 |
Compound E |
||
| GL3746-250UG | 250 ug | EUR 206.4 |
Compound E |
||
| GL3746-5MG | 5 mg | EUR 1197.6 |
Compound 2 |
||
| HY-U00358 | 10mg | EUR 7249.2 |
Compound E |
||
| HY-14176 | 10mM/1mL | EUR 832.8 |
Compound 34 |
||
| GL2080-1 | 1 | EUR 351.9 |
Compound 34 |
||
| GL2080-200 | 200 | EUR 139.6 |
Compound E |
||
| GL3746-1 | 1 | EUR 263.4 |
Compound E |
||
| GL3746-250 | 250 | EUR 133.6 |
Compound E |
||
| GL3746-5 | 5 | EUR 853.3 |
Compound CL0485 |
||
| ADC-P-074 | unit | Ask for price |
Compound 112254 hydrochloride |
||
| GL8859-10MG | 10 mg | EUR 199.2 |
Compound 112254 hydrochloride |
||
| GL8859-50MG | 50 mg | EUR 550.8 |
Compound 112254 hydrochloride |
||
| GL8859-10 | 10 | EUR 139.6 |
Compound 112254 hydrochloride |
||
| GL8859-50 | 50 | EUR 440.4 |
APHA Compound 8 |
||
| M45003 | 1 mg | EUR 341.88 |
Teijin compound 1 |
||
| B5468-10 | 10 mg | EUR 466.8 |
Teijin compound 1 |
||
| B5468-50 | 50 mg | EUR 1771.2 |
GPR120 Compound A |
||
| C5824-10 | 10 mg | EUR 351.6 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
GPR120 Compound A |
||
| C5824-5 | 5 mg | EUR 236.4 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
GPR120 Compound A |
||
| C5824-50 | 50 mg | EUR 1104 |
|
Description: GPR120 Compound A is an orally active and high-affinity agonist of GPR120 [1].G-protein coupled receptor 120 is a G protein-coupled receptor which has been expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. |
||
Teijin compound 1 |
||
| HY-108323 | 5mg | EUR 374.4 |
Imidazoquinoline Compound |
||
| VAdv-Ly0028 | 5 mg | EUR 3936 |
|
Description: Imidazoquinoline compound, a TLR7 agonist vaccine adjuvant. |
||
NPS ALX Compound 4a |
||
| HY-103090 | 5mg | EUR 349.2 |
Dorsomorphin (Compound C) |
||
| B3252-10 | 10 mg | EUR 164.4 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Dorsomorphin (Compound C) |
||
| B3252-5 | 5 mg | EUR 129.6 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Dorsomorphin (Compound C) |
||
| B3252-50 | 50 mg | EUR 408 |
|
Description: Dorsomorphin is a cell-permeable and reversible ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with Ki value of 109nM [1].Dorsomorphin is highly selective against AMPK over other structure related kinases such as protein kinase A, protein kinase C and Janus kinase 3. |
||
Antiasthmatic Compound 1 |
||
| HY-U00409 | 1mg | EUR 1018.8 |
Antibacterial compound 2 |
||
| HY-101730 | 5mg | EUR 9580.8 |
Antibacterial compound 1 |
||
| HY-101819 | 5mg | EUR 2637.6 |
PKM2 inhibitor(compound 3k) |
||
| B8217-25 | 25 mg | EUR 494.4 |
PKM2 inhibitor(compound 3k) |
||
| B8217-5 | 5 mg | EUR 201.6 |
Asthma relating compound 1 |
||
| HY-U00412 | 5mg | EUR 3415.2 |
Itch-Targeting Compound 1 |
||
| HY-U00361 | 20mg | EUR 13416 |
8-hydroxy Guanosine, compound |
||
| 8OHG15-N-1 | 1 mg | EUR 242.4 |
8-hydroxy Guanosine, compound |
||
| 8OHG15-N-5 | 5 mg | EUR 708 |
CCT251545 analogue, Compound 51 |
||
| A8739-25 | 25 mg | EUR 1730.4 |
|
Description: CCT251545 analogue, Compound 51 is a potent and selective CDK8/19 inhibitor with IC50 values of 5.1 nM and 5.6 nM, respectively [1]. Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. |
||
CCT251545 analogue, Compound 51 |
||
| A8739-5 | 5 mg | EUR 547.2 |
|
Description: CCT251545 analogue, Compound 51 is a potent and selective CDK8/19 inhibitor with IC50 values of 5.1 nM and 5.6 nM, respectively [1]. Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. |
||
Cancer-Targeting Compound 1 |
||
| HY-U00300 | 1mg | EUR 1018.8 |
Horsley Compound Action Angled |
||
| INS6130 | EACH | EUR 320.4 |
Imidazol-1-yl compound 1 |
||
| HY-U00322 | 10mg | EUR 4440 |
Arrhythmic-Targeting Compound 1 |
||
| HY-U00393 | 5mg | EUR 11233.2 |
Arrhythmias-Targeting Compound 1 |
||
| HY-101750 | 20mg | EUR 6819.6 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-.1 | 100 uL/well(10 mM solution) | EUR 5683.2 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-.25 | 250 uL/well(10 mM solution) | EUR 10221.6 |
DiscoveryProbe? GPCR Compound Library |
||
| L1025-5 | 5 mg/well | EUR 13284 |
Neuromuscular-targeting compound 1 |
||
| HY-U00310 | 20mg | EUR 5763.6 |
NPS ALX Compound 4a dihydrochloride |
||
| B7344-10 | 10 mg | EUR 439.2 |
NPS ALX Compound 4a dihydrochloride |
||
| B7344-50 | 50 mg | EUR 1654.8 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-.1 | 100 uL/well(10 mM solution) | EUR 28066.8 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-.25 | 250 uL/well(10 mM solution) | EUR 50450.4 |
DiscoveryProbe? Bioactive Compound Library |
||
| L1022-5 | 5 mg/well | EUR 65623.2 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-.1 | 100 uL/well(10 mM solution) | EUR 13408.8 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-.25 | 250 uL/well(10 mM solution) | EUR 24141.6 |
DiscoveryProbe? Autophagy Compound Library |
||
| L1031-5 | 5 mg/well | EUR 31380 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-.1 | 100 uL/well(10 mM solution) | EUR 4166.4 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-.25 | 250 uL/well(10 mM solution) | EUR 7437.6 |
DiscoveryProbe? Apoptosis Compound Library |
||
| L1036-5 | 5 mg/well | EUR 9664.8 |
S-Nitroso-L-Glutathione, compound |
||
| SNOG15-N-10 | 10 mg | EUR 300 |
S-Nitroso-L-Glutathione, compound |
||
| SNOG15-N-5 | 5 mg | EUR 226.8 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-.1 | 100 uL/well(10 mM solution) | EUR 7144.8 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-.25 | 250 uL/well(10 mM solution) | EUR 12866.4 |
DiscoveryProbe? Epigenetics Compound Library |
||
| L1029-5 | 5 mg/well | EUR 16764 |
DiscoveryProbe? JAK/STAT Compound Library |
||
| L1041-.1 | 100 uL/well(10 mM solution) | EUR 2704.8 |
DiscoveryProbe? JAK/STAT Compound Library |
||
| L1041-.25 | 250 uL/well(10 mM solution) | EUR 4792.8 |
DiscoveryProbe? JAK/STAT Compound Library |
||
| L1041-5 | 5 mg/well | EUR 6184.8 |
DiscoveryProbe? Stem Cell Compound Library |
||
| L1040-.1 | 100 uL/well(10 mM solution) | EUR 5223.6 |
DiscoveryProbe? Stem Cell Compound Library |
||
| L1040-.25 | 250 uL/well(10 mM solution) | EUR 9386.4 |
DiscoveryProbe? Stem Cell Compound Library |
||
| L1040-5 | 5 mg/well | EUR 12170.4 |
Horsley Compound Action Straight 10.5 Inch |
||
| INS6136 | EACH | EUR 132 |
DiscoveryProbe? Ion Channel Compound Library |
||
| L1030-.1 | 100 uL/well(10 mM solution) | EUR 6672 |
DiscoveryProbe? Ion Channel Compound Library |
||
| L1030-.25 | 250 uL/well(10 mM solution) | EUR 11863.2 |
DiscoveryProbe? Ion Channel Compound Library |
||
| L1030-5 | 5 mg/well | EUR 15482.4 |
Urinary Incontinence-Targeting Compound 1 |
||
| HY-U00357 | 1mg | EUR 2506.8 |
8-hydroxy-2-deoxy Guanosine, compound |
||
| 8OH2G16-N-1 | 1 mg | EUR 285.6 |
8-hydroxy-2-deoxy Guanosine, compound |
||
| 8OH2G16-N-5 | 5 mg | EUR 708 |
DiscoveryProbe? Anti-cancer Compound Library |
||
| L1023-.1 | 100 uL/well(10 mM solution) | EUR 24363.6 |
DiscoveryProbe? Anti-cancer Compound Library |
||
| L1023-.25 | 250 uL/well(10 mM solution) | EUR 43768.8 |
DiscoveryProbe? Anti-cancer Compound Library |
||
| L1023-5 | 5 mg/well | EUR 56853.6 |
Neuromuscular Disorder-Targeting Compound 1 |
||
| HY-U00385 | 1mg | EUR 4125.6 |
Tissue-Tek |
||
| abx082403-118ml | 118 ml | EUR 276 |
DiscoveryProbe? Anti-diabetic Compound Library |
||
| L1046-.1 | 100 uL/well(10 mM solution) | EUR 866.4 |
DiscoveryProbe? Anti-diabetic Compound Library |
||
| L1046-.25 | 250 uL/well(10 mM solution) | EUR 1507.2 |
DiscoveryProbe? Anti-diabetic Compound Library |
||
| L1046-5 | 5 mg/well | EUR 1939.2 |
DiscoveryProbe? Anti-infection Compound Library |
||
| L1027-.1 | 100 uL/well(10 mM solution) | EUR 8439.6 |
DiscoveryProbe? Anti-infection Compound Library |
||
| L1027-.25 | 250 uL/well(10 mM solution) | EUR 15093.6 |
DiscoveryProbe? Anti-infection Compound Library |
||
| L1027-5 | 5 mg/well | EUR 19548 |
Clarithromycin related compound M EvoPure® |
||
| C135-5MG | 5 mg | EUR 267.6 |
Clarithromycin related compound D EvoPure® |
||
| C140-5MG | 5 mg | EUR 412.8 |
Clarithromycin related compound H EvoPure® |
||
| C143-5MG | 5 mg | EUR 583.2 |
Clarithromycin related compound C EvoPure® |
||
| C128-10MG | 10 mg | EUR 441.6 |
Clarithromycin related compound I EvoPure® |
||
| C131-10MG | 10 mg | EUR 441.6 |
Clarithromycin related compound J EvoPure® |
||
| C132-10MG | 10 mg | EUR 441.6 |
Clarithromycin related compound K EvoPure® |
||
| C133-10MG | 10 mg | EUR 441.6 |
Clarithromycin related compound L EvoPure® |
||
| C134-10MG | 10 mg | EUR 804 |
Clarithromycin related compound Z EvoPure® |
||
| E022-10MG | 10 mg | EUR 804 |
DiscoveryProbe? PI3K/Akt/mTOR Compound Library |
||
| L1034-.1 | 100 uL/well(10 mM solution) | EUR 4500 |
DiscoveryProbe? PI3K/Akt/mTOR Compound Library |
||
| L1034-.25 | 250 uL/well(10 mM solution) | EUR 7994.4 |
DiscoveryProbe? PI3K/Akt/mTOR Compound Library |
||
| L1034-5 | 5 mg/well | EUR 10360.8 |
Neurodegenerative Disorder-Targeting Compound 1 |
||
| HY-U00362 | 5mg | EUR 4292.4 |
DiscoveryProbe? TGF-beta/Smad Compound Library |
||
| L1045-.1 | 100 uL/well(10 mM solution) | EUR 1966.8 |
DiscoveryProbe? TGF-beta/Smad Compound Library |
||
| L1045-.25 | 250 uL/well(10 mM solution) | EUR 3456 |
DiscoveryProbe? TGF-beta/Smad Compound Library |
||
| L1045-5 | 5 mg/well | EUR 4500 |
Sulfamethoxazole related compound A EvoPure® |
||
| S063-25MG | 25 mg | EUR 180 |
Sulfamethoxazole related compound A EvoPure® |
||
| S063-500MG | 500 mg | EUR 459.6 |
Sulfamethoxazole related compound B EvoPure® |
||
| S064-100MG | 100 mg | EUR 400.8 |
DiscoveryProbe? Metabolism-related Compound Library |
||
| L1032-.1 | 100 uL/well(10 mM solution) | EUR 10291.2 |
DiscoveryProbe? Metabolism-related Compound Library |
||
| L1032-.25 | 250 uL/well(10 mM solution) | EUR 18434.4 |
DiscoveryProbe? Metabolism-related Compound Library |
||
| L1032-5 | 5 mg/well | EUR 24002.4 |
DiscoveryProbe? Immunology/Inflammation Compound Library |
||
| L1042-.1 | 100 uL/well(10 mM solution) | EUR 4068 |
DiscoveryProbe? Immunology/Inflammation Compound Library |
||
| L1042-.25 | 250 uL/well(10 mM solution) | EUR 7298.4 |
DiscoveryProbe? Immunology/Inflammation Compound Library |
||
| L1042-5 | 5 mg/well | EUR 9525.6 |
Anti-FOLH1 (clone 2A10)-cytotoxin Compound A ADC |
||
| ADC-W-118 | 1mg | Ask for price |
|
Description: This ADC product is comprised of an anti-FOLH1 monoclonal antibody conjugated via a linker to cytotoxin Compound A |
||
Human thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| 201-12-1124 | 96 tests | EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
||
Human thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| CN-04100H1 | 96T | EUR 583.2 |
Human thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| CN-04100H2 | 48T | EUR 403.2 |
Human thrombinthrombomodulin compound(T-TM)ELISA Kit |
||
| GA-E1140HM-48T | 48T | EUR 346.8 |
Human thrombinthrombomodulin compound(T-TM)ELISA Kit |
||
| GA-E1140HM-96T | 96T | EUR 559.2 |
Human thrombinthrombomodulin compound(T-TM)ELISA Kit |
||
| QY-E02032 | 96T | EUR 472.8 |
Human thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| YLA0473HU-48T | 48T | EUR 435 |
Human thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| YLA0473HU-96T | 96T | EUR 562.5 |
Mouse thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| YLA1238MO-48T | 48T | EUR 465 |
Mouse thrombinthrombomodulin compound,T-TM ELISA Kit |
||
| YLA1238MO-96T | 96T | EUR 600 |
PLATEMAX PEELABLE HEAT SEALING FILM FOR COMPOUND STORAGE. 100/500 |
||
| HS-400 | 100/pk | EUR 364.8 |
|
Description: Sealing Products; Sealing films - Axygen |
||
Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade |
||
| AV-8020-1 | 1 mg | EUR 343.2 |
Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade |
||
| AV-8020-5 | 5 mg | EUR 562.8 |
Max III Trinocular Compound Microscope with Achromatic Objectives |
||
| SLS2270 | EACH | EUR 1194 |
Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade |
||
| R848-1 | 1 mg | EUR 343.2 |
Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade |
||
| R848-5 | 5 mg | EUR 562.8 |
Max III Trinocular Compound Microscope with Plan Achromatic Objectives |
||
| SLS2272 | EACH | EUR 1525.2 |
PLATEMAX PEELABLE HEAT SEALING FILM FOR LOW TEMPERATURE COMPOUND STORAGE AND PCR. 100/500 |
||
| HS-200 | 100/pk | EUR 364.8 |
|
Description: Sealing Products; Sealing films - Axygen |
||